1. Home
  2. NGNE vs LOCO Comparison

NGNE vs LOCO Comparison

Compare NGNE & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$17.20

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$10.72

Market Cap

304.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
LOCO
Founded
2003
1980
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
304.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
LOCO
Price
$17.20
$10.72
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
$40.14
$14.50
AVG Volume (30 Days)
92.0K
184.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.42
Revenue Next Year
N/A
$1.67
P/E Ratio
N/A
$12.06
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$8.29
52 Week High
$37.27
$12.49

Technical Indicators

Market Signals
Indicator
NGNE
LOCO
Relative Strength Index (RSI) 43.48 50.77
Support Level $16.78 $10.23
Resistance Level $17.93 $10.98
Average True Range (ATR) 1.29 0.27
MACD 0.04 0.02
Stochastic Oscillator 31.24 69.40

Price Performance

Historical Comparison
NGNE
LOCO

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

Share on Social Networks: